MS treatment showdown: which drug wins on cost and disability?

NCT ID NCT01065727

Completed Disease control Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 144 people with aggressive relapsing multiple sclerosis to compare two treatment plans over three years: monthly natalizumab infusions versus a six-month course of mitoxantrone followed by another immune-modulating drug. Researchers measured cost-effectiveness, disability progression, and quality of life. The goal was to find which strategy offers better value and outcomes for patients with this severe form of MS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: natalizumab and mitoxantrone
What this could lead to: If successful, this could help doctors choose the most cost-effective and disability-slowing treatment for aggressive multiple sclerosis.
What could go wrong: This is a completed cost-effectiveness study, not a new drug trial. Results may not apply to all MS patients, and both treatments have known risks like infections or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

CHU Cavale Blanche

Brest, 29609, France
CHU Rennes

Rennes, 35033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.